A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

The purpose of this study is to describe the reasons, therapy, and/or disease for changing first or second line Disease Modifying Therapy (DMT) to ozanimod in participants with Relapsing Remitting Multiple Sclerosis (RRMS).

Inclusion Criteria:Patients with RRMS according to 2017 revised McDonald criteriaPatients who switched a previous first or second line DMT to ozanimod between 4 and 12 weeks before the enrollmentPatient with a MRI performed within three months before the enrollmentPatient eligible to ozanimod according to SmPCExclusion Criteria:Patients with clinical forms of MS other than RRMSPatients unable to participate for various reasonsPatients participating in another clinical study with an investigational product if the study considers the switching behavior as an endpoint or objectiveContraindications to ozanimod according to SmPCOther protocol-defined Inclusion/Exclusion Criteria apply.